Company intelligence / Profile preview
Shandong New Time Pharmaceutical
- Ownership
- Private
- Employees
- ~5000
- Development stage
- Commercial
Overview
Shandong New Time Pharmaceutical is a major Chinese pharmaceutical manufacturer specializing in APIs, finished dosage forms, traditional Chinese medicines, chemical drugs, and biologics. It has several commercial products globally and an active clinical development pipeline including small molecules and biologics such as monoclonal antibodies. Notably, its anti-PD1 antibody Rulonilimab is in Phase II trials for cervical cancer.
- Therapeutic areas
- GastroenterologyOncologyPulmonology
- Modalities
- Small moleculeMonoclonal antibodyBiosimilarHerbal medicineBispecific monoclonal antibody (BiTE)
- Industry
- Pharma
Drug pipeline
14 assets13 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Shandong New Time Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shandong New Time Pharmaceutical.